Dr. Tarek M. Sabagh
Claim this profileMiami Valley Hospital South
Expert in Cancer
Expert in Lung Cancer
67 reported clinical trials
123 drugs studied
About Tarek M. Sabagh
Education:
- Obtained a Medical degree (MD) from the American University of Beirut Faculty of Medicine, Lebanon, in 2007.
- Completed Residency in Internal Medicine at the University of Cincinnati Medical Center, Ohio (2008-2011).
- Undertook a Fellowship in Gastroenterology and Hepatology at the University of Cincinnati Medical Center, Ohio (2011-2014).
Experience:
- Currently practices as a gastroenterologist at Miami Valley Hospital South.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Tarek M. Sabagh is currently running
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting1 award Phase 221 criteria
More about Tarek M. Sabagh
Clinical Trial Related4 years of experience running clinical trials · Led 67 trials as a Principal Investigator · 50 Active Clinical TrialsTreatments Tarek M. Sabagh has experience with
- Nivolumab
- Pembrolizumab
- Carboplatin
- Cisplatin
- Ipilimumab
- Atezolizumab
Breakdown of trials Tarek M. Sabagh has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tarek M. Sabagh specialize in?
Tarek M. Sabagh focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Tarek M. Sabagh currently recruiting for clinical trials?
Yes, Tarek M. Sabagh is currently recruiting for 49 clinical trials in Centerville Ohio. If you're interested in participating, you should apply.
Are there any treatments that Tarek M. Sabagh has studied deeply?
Yes, Tarek M. Sabagh has studied treatments such as Nivolumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Tarek M. Sabagh?
Apply for one of the trials that Tarek M. Sabagh is conducting.
What is the office address of Tarek M. Sabagh?
The office of Tarek M. Sabagh is located at: Miami Valley Hospital South, Centerville, Ohio 45459 United States. This is the address for their practice at the Miami Valley Hospital South.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.